Endoplasmic Reticulum Stress Regulator XBP-1 Contributes to Effector CD8+ T Cell Differentiation during Acute Infection

Daisuke Kamimura and Michael J. Bevan

*J Immunol* 2008; 181:5433-5441; doi: 10.4049/jimmunol.181.8.5433

http://www.jimmunol.org/content/181/8/5433

**References**

This article cites 50 articles, 25 of which you can access for free at:

http://www.jimmunol.org/content/181/8/5433.full#ref-list-1

**Subscription**

Information about subscribing to *The Journal of Immunology* is online at:

http://jimmunol.org/subscription

**Permissions**

Submit copyright permission requests at:

http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**

Receive free email-alerts when new articles cite this article. Sign up at:

http://jimmunol.org/alerts

---

*The Journal of Immunology* is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2008 by The American Association of Immunologists All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
Endoplasmic Reticulum Stress Regulator XBP-1 Contributes to Effector CD8\(^+\) T Cell Differentiation during Acute Infection\(^1\)

Daisuke Kamimura and Michael J. Bevan\(^2\)

The transcription factor X-box-binding protein-1 (XBP-1) plays an essential role in activating the unfolded protein response in the endoplasmic reticulum (ER). Transcribed XBP-1 mRNA is converted to its active form by unconventional cytoplasmic splicing mediated by inositol-requiring enzyme-1 (IRE-1) upon ER stress. We report activation of the IRE-1/XBP-1 pathway in effector CD8\(^+\) T cells during the response to acute infection. Transcription of unspliced XBP-1 mRNA is up-regulated by IL-2 signals, while its splicing is induced after TCR ligation. Splicing of XBP-1 mRNA was evident during the expansion of Ag-specific CD8\(^+\) T cells in response to viral or bacterial infection. An XBP-1 splicing reporter revealed that splicing activity was enriched in terminal effector cells expressing high levels of killer cell lectin-like receptor G1 (KLRG1). Overexpression of the spliced form of XBP-1 in CD8\(^+\) T cells enhanced KLRG1 expression during infection, whereas XBP-1\(^{-/-}\) CD8\(^+\) T cells or cells expressing a dominant-negative form of XBP-1 showed a decreased proportion of KLRG1\(^{high}\) effector cells. These results suggest that, in the response to pathogen, activation of ER stress sensors and XBP-1 splicing contribute to the differentiation of end-stage effector CD8\(^+\) T cells.


The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the Howard Hughes Medical Institute and by Grant AI19335 from the National Institutes of Health (to M.J.B.).

2 Address correspondence and reprint requests to Dr. Michael J. Bevan, Department of Immunology, Office 1604H Health Science Center, Box 357370, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195-7370. E-mail address: mbevan@u.washington.edu

Copyright © 2008 by The American Association of Immunologists, Inc. 0022-1767/08/S2.00

www.jimmunol.org
domain in the N terminus, and a degradation motif and nuclear exclusion signal in the C terminus (18). Upon ER stress, IRE-1 is activated and splices out the 26-nt intron, causing a frame shift of the coding region of XBP-1. The resulting spliced form (XBP-1s) encodes a longer polypeptide that retains the DNA binding domain, with a newly generated transactivating domain in the C terminus (16, 17). Microarray analyses using XBP1−/− embryonic fibroblasts under ER stress revealed several XBP-1-dependent UPR target genes including ERdj4, PSIP1, EDEM, RAMP-4, PDI-P5, and HEDJ (19). In addition to genes involved in UPR, XBP-1 binds to a diverse set of genes in a cell type- and condition-specific manner (20). In vitro studies have shown that cells that have adapted to chronic ER stress by activating UPR become more resistant to subsequent stress, whereas those that have failed to adapt undergo apoptosis (21). When IRE-1 activity was artificially stimulated in human cell lines, cell survival was enhanced upon ER stress in vitro (22), suggesting that the IRE-1/XBP-1 axis affects the cell fate decision between cell death and survival.

XBP-1−/− mice die before birth from anemia associated with hypoplasia in the fetal liver (23). Hepatocyte-specific transgenic expression of XBP-1 rescues the embryonic lethality of XBP-1−/− mice, but these animals display abnormalities in other secretory organs such as the pancreas, leading to neonatal death (24). In the immune system, RAG2−/−/− blastocyst complementation revealed an essential role for XBP-1 in the generation of plasma cells. XBP-1−/− B cells develop normally, undergo class-switch recombination, and form germinal centers upon activation, but they fail to secrete IgG (25). In B cells, transcription of XBP-1-dependent mRNA is directly up-regulated by IL-4 signaling, but splicing to XBP-1s is dependent on additional signals that induce synthesis of IgGs during differentiation into plasma cells (26). Surprisingly, it has recently been shown that XBP-1 is also important for the development and survival of dendritic cells that are not known to be highly secretory (27).

In this study, we identified XBP-1 as an IL-2-induced gene in CD8+ T cells in vivo, and demonstrate the activation of the IRE-1/XBP-1 splicing machinery in effector CD8+ T cells during acute infection.

Materials and Methods

Mice

C57BL/6d mice were obtained from The Jackson Laboratory. OVA-specific OT-I TCR transgenic mice on the RAG1−/− background (OT-I/ RAG1−/−) were purchased from Taconic Farms. XBP-1/RAG2−/− blastocyst chimeras (25) and 129/RAG2−/−/− control chimeras were provided by L. Glomcher (Harvard School of Public Health, Boston, MA). These blastocyst chimeras were used for generation of secondary bone marrow chimeric mice using 10 Gy-irradiated C57BL/6 mice as hosts. XBP-1−/− CD8+ T cells (129 strain origin) were detected by the CD229 marker (30C7; BD Biosciences). ETRA transgenic mice (28) were obtained from the RIKEN BioResource Center (Ibaraki, Japan) with the kind approval of H. Shen (University of Pennsylvania School of Medicine, Philadelphia, PA). LCMV-OWA and LM-GFP were grown as previously described (12). LCMV was grown on BHK cells and was titrated on Vero cells. For bacteria infection, mice were injected i.v. with a priming dose of 3000 CFU and a challenge dose of 1–2 × 10^4 CFU. For LCMV infection, a dose of 2 × 10^6 PFU was i.p. injected. Ampicillin treatment of Listeria-infected mice was performed as previously described (30).

Western blot analysis

CD8+ T cells were stimulated for 2 days with 1 µg/ml each of anti-CD3 (145-2C11) and anti-CD28 (37.51) on a dish preseeded with 300 µg/ml anti-hamster IgG (Jackson ImmunoResearch Laboratories), and then maintained in RPMI 1640 medium (Invitrogen) containing 10% FCS, antibiotics, and 100 U/ml recombinant IL-2 (eBioscience). A few days later, these cells were stimulated with plate-bound anti-CD3 and anti-CD28 mAbs for the indicated time periods. A proteasome inhibitor MG132 (Calbiochem) was added to the culture at 1 µM for the last 1 h of the incubation to detect rapidly degraded XBP-1 protein (16, 31). The sample at 0 h was cultured for 1 h with MG132. Total cell lysates equivalent to 2 × 10^6 cells were separated on SDS-PAGE, transferred to polyvinylidene difluoride membranes, and probed with anti-XBP-1 Ab (M-186; Santa Cruz Biotechnology). Donkey anti-rabbit IgG-HRP (GE Healthcare) was used as the secondary Ab, and signals were detected using the ECL western blotting detection kit (GE Healthcare).

RT-PCR and real-time PCR of XBP-1 mRNA

To distinguish XBP-1u and XBP-1s mRNAs, a region encompassing the splicing site of XBP-1 was amplified by RT-PCR with saturating cycles, followed by digestion with PsiI, whose recognition site is located within the 26-nt intron of XBP-1 mRNA (17). For real-time PCR, a primer set was designed to bind upstream of the splicing site to detect total XBP-1 transcripts, including both XBP-1u and XBP-1s mRNA in the same product size. Real-time PCR was performed using the SuperScript III Platinum Two-Step QRT-PCR kit with SYBR Green (Invitrogen). Mouse recombinant IL-2, IL-4, IL-6, and IL-12 and human recombinant IL-15 were obtained from BD Biosciences, eBioscience, and PeproTech.

Retroviral transduction of CD8+ T cells

Retroviruses were produced using Phoenix-E cells transduced with pMIt (MSCV-IRE- Thy1.1) vector (32), a gift from P. Marrack (National Jewish Medical and Research Center, Denver, CO). XBP-1u and XBP-1s CDNA were isolated by PCR using cDNA from a mouse melanoma cell line. To prevent IRE-1-mediated splicing of transduced XBP-1u, point mutations were introduced without amino acid substitutions at critical regions for the splicing (16). The XBP-1 splicing reporter construct, F-XBP1-ΔBBD-Venus, was a gift from M. Miura (Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan) (28). GFP-RV vector (33) containing T-bet cDNA was provided by L. Glomcher (Harvard School of Public Health, Boston, MA). The dominant-negative form of OT-I/ RAG2−/−/− cells were spliced with plate-bound anti-CD3 and anti-CD28 mAbs, as described earlier. The activated OT-I/ RAG1−/−/− cells were spin-infected with retroviruses on days 2 and 3 in the presence of 4 µg/ml polybrene (Sigma-Aldrich) and 100 U/ml IL-2, and maintained for 2–3 days in IL-2-containing medium until sorting. For Fig. 3F, transduced OT-I T cells were obtained from bone marrow chimera mice that have been transplanted with retrovirus-infected OT-I bone marrow cells (35). Thy1.1+ transduced cells were sorted using a FACSAria, and 10^5 cells/mouse were transferred i.v. into B6 mice. These animals were infected with LM-OVA on the same day or 1 day later.

Flow cytometry

Splenocytes and peripheral blood leukocytes were stained with fluorochrome-conjugated goat IgG1 isotype control, permeabilized with Brefeldin-PE in PBS containing 2% FCS and anti-CD16/CD56 mAb (24G2), Phospho-STAT5 staining was performed as described (12). For intracellular cytokine staining, splenocytes were incubated with 100 ng/ml

ACTIVATION OF XBP-1 IN EFFECTOR CD8+ T CELLS

- Spleenocytes and peripheral blood leukocytes were stained with fluorochrome-conjugated goat IgG1 isotype control, permeabilized with Brefeldin-PE in PBS containing 2% FCS and anti-CD16/CD56 mAb (24G2).
- Phospho-STAT5 staining was performed as described (12).
- For intracellular cytokine staining, splenocytes were incubated with 100 ng/ml.
FIGURE 1. XBP-1u mRNA is up-regulated in CD8\(^+\) T cells following IL-2 complex treatment in vivo. A, STAT5 phosphorylation of CD8\(^+\) T cells after IL-2 complex injection (top row) and purity of the sorted samples for DNA microarray analysis (bottom row). B, Up-regulation of total XBP-1 mRNA in CD8\(^+\) T cells after IL-2 complex treatment assayed by real-time PCR. Data represent the mean ± SEM (n = 2 experiments). C, Splicing status of XBP-1 mRNA detected by RT-PCR plus PstI digestion. cDNA from a mouse melanoma cell line treated with tunicamycin (Tm) for 6 h, and XBP-1u and XBP-1s cDNA were used as control templates for this assay. D, OT-I/RAG1\(^-/-\) CD8\(^+\) T cell blasts that had been rested overnight without IL-2 were stimulated with cytokines (10 ng/ml) for the indicated periods before real-time PCR was performed for total XBP-1 mRNA.

Statistical analysis

Statistical differences between groups were examined by a one-way ANOVA with Bonferroni’s multiple comparison test or by an unpaired Student’s t test using Prism software (GraphPad). A value of p < 0.05 was considered statistically significant.

Table I. Genes induced in CD8\(^+\) T cells by IL-2 complex treatment

<table>
<thead>
<tr>
<th>Gene Title</th>
<th>Gene Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphotixin A</td>
<td>Lta</td>
</tr>
<tr>
<td>Regulator of G protein signaling 1</td>
<td>Rgs1</td>
</tr>
<tr>
<td>Cytokine inducible Src homology 2-containing protein</td>
<td>Cish</td>
</tr>
<tr>
<td>MAPK kinase kinase 8</td>
<td>Map3k8</td>
</tr>
<tr>
<td>X-box-binding protein-1</td>
<td>Xbp1</td>
</tr>
<tr>
<td>B cell leukemia/lymphoma 2</td>
<td>Bcl2</td>
</tr>
<tr>
<td>Early growth response 1</td>
<td>Egr1</td>
</tr>
<tr>
<td>AXIN1 up-regulated 1</td>
<td>Axud1</td>
</tr>
<tr>
<td>CD69</td>
<td>CD69</td>
</tr>
<tr>
<td>Suppressor of cytokine signaling 1</td>
<td>Socs1</td>
</tr>
<tr>
<td>Signaling lymphocytic activation molecule family member 1</td>
<td>Slomf1</td>
</tr>
<tr>
<td>A disintegrin and metallopeptidase domain 19</td>
<td>Adam19</td>
</tr>
<tr>
<td>Activating transcription factor 4</td>
<td>Atf4</td>
</tr>
<tr>
<td>Myelocytomatosis oncogene</td>
<td>Muc</td>
</tr>
<tr>
<td>FBJ osteosarcoma oncogene</td>
<td>Fos</td>
</tr>
<tr>
<td>Jun oncogene</td>
<td>Jun</td>
</tr>
<tr>
<td>Secreted frizzled-related protein 2</td>
<td>SFRP2</td>
</tr>
<tr>
<td>cDNA sequence BC023892</td>
<td>BC023892</td>
</tr>
<tr>
<td>Kruppel-like factor 6</td>
<td>Klf6</td>
</tr>
<tr>
<td>RAS p21 protein activator 2</td>
<td>Rasa2</td>
</tr>
<tr>
<td>Solute carrier family 30, member 4</td>
<td>SLC30A4</td>
</tr>
<tr>
<td>NF of (\alpha) light polypeptide gene enhancer in B cell inhibitor, (\zeta)</td>
<td>Nfkbic</td>
</tr>
</tbody>
</table>

\(^{a}\) Fold change relative to 0 h is shown as a log2 value.

Results

XBP-1 is an IL-2 target gene in CD8\(^+\) T cells in vivo

To understand the mechanisms by which IL-2 signals control CD8\(^+\) T cell responses, we conducted a genome-wide expression analysis. We used injection of IL-2 complex to deliver IL-2 signals to all CD8\(^+\) T cells in vivo. Because STAT5 phosphorylation peaked 1 h after injection of the IL-2 complex (12) (Fig. 1A), gene expression in CD8\(^+\) T cells was compared at 0 h (no treatment), 1 h, and 3 h posttreatment (Fig. 1A). Tables I and II show genes that were up-regulated and down-regulated more than 4-fold at 1
vs 0 h. A full list can be found in the Gene Expression Omnibus database (GSE11446). In the present study, we focused on XBP-1 because this transcription factor was found to be most up-regulated by IL-2 signals (Table I), and because XBP-1 is known to be critically involved in the differentiation and survival of immune cells, including plasma cells and dendritic cells (25, 27). Real-time PCR confirmed the up-regulation of total XBP-1 transcripts in CD8 T cells after IL-2 complex treatment (Fig. 1B). XBP-1u and XBP-1s messages can be distinguished in size by RT-PCR combined with restriction enzyme digestion (17). Although IL-2 complex treatment increased the total amount of XBP-1 mRNA in CD8 T cells, it did not induce the conversion of XBP-1u to XBP-1s by 3 h (Fig. 1C), at which point, STAT5 phosphorylation and XBP-1 induction had already begun to fade (Fig. 1, A and B). IL-2 complex treatment in vivo activates STAT5 signaling in CD8 T cells as early as 15 min after treatment (12), suggesting the direct action of IL-2 signals on XBP-1 mRNA induction in CD8 T cells in vivo. In support of this idea, we found that in vitro stimulation with IL-2 up-regulated XBP-1 mRNA in purified CD8 T cell blasts (Fig. 1D), which formally excluded the possibility of a secondary effect of the complex through another cell type expressing the IL-2R. In addition to IL-2, IL-4 and IL-15 also increased total XBP-1 mRNA levels in CD8 T cells in vitro (Fig. 1D). These results demonstrate that IL-2 signals induce XBP-1u mRNA in CD8 T cells, but they do not generate the spliced, transcriptionally active form of XBP-1.

**TCR ligation induces the generation of XBP-1s in vitro**

We next tested whether TCR cross-linking induces the generation of XBP-1s. CD8+ T cells were activated by plate-bound anti-CD3 and anti-CD28 mAbs, and the CD8+ T cell blasts maintained for several days in IL-2-containing medium. No obvious increase of XBP-1s mRNA was detected during culture with IL-2 alone (Fig. 2A at 0 h and an additional 24-h culture without TCR ligation). In contrast, restimulation with anti-CD3 and anti-CD28 mAbs clearly induced splicing and XBP-1s accumulation in CD8+ T cell blasts (Fig. 2A). This observation was also confirmed at the protein level by Western blot (Fig. 2B). We noted that XBP-1s gradually disappeared 8–24 h after TCR stimulation (Fig. 2, A and B). These results suggest that whereas IL-2 up-regulates XBP-1 transcripts, antigen stimulation through the TCR is required for the generation of transcriptionally active XBP-1s.

**Activation of the IRE-1/XBP-1 pathway in effector CD8+ T cells during acute infection**

Acute infection with viruses or bacteria induces vigorous expansion of Ag-specific CD8+ T cells. We hypothesized that these dynamic CD8+ T cell responses involving both inflammatory and antigenic stimuli would activate the IRE-1/XBP-1 pathway. After LCMV infection, most of the CD8+ T cell population consists of LCMV-specific effector cells 8 days postinfection (p.i.) (36). Total CD8+ T cells in the spleen of LCMV-infected C57BL/6J mice were examined 8 days p.i. for XBP-1 mRNA splicing. As shown in Fig. 3A, whereas CD8+ T cells from uninfected mice contained no or little XBP-1s mRNA, LCMV infection clearly induced IRE-1-mediated splicing and generated XBP-1s mRNA in CD8+ T cells.

To investigate XBP-1 splicing status in different subsets of effector CD8+ T cells, we used transgenic mice that ubiquitously express an XBP-1 splicing reporter, referred to as ER stress-activated indicator, ERAI (28). In this system, Venus (a GFP variant) is expressed only in cells that contain XBP-1splicing activity (Fig. 3B). Consistent with the previous report showing that dendritic cells constitutively activate the XBP-1 pathway (27), unstimulated splenic CD11c-CD8+ dendritic cells from the ERAI transgenic mice were positive for Venus-GFP (Fig. 3C). Before infection, CD8+ T cells from various organs of the ERAI mice showed no detectable signal of XBP-1 splicing activity (data not shown). However, gp135-specific effector cells from LCMV-infected

---

Table II. **Genes repressed in CD8+ T cells by IL-2 complex treatment**

<table>
<thead>
<tr>
<th>1 h/0 h</th>
<th>3 h/0 h</th>
<th>Gene Title</th>
<th>Gene Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>−3.4</td>
<td>−1.5</td>
<td>Similar to mouse RING finger 1</td>
<td>LOC6360539</td>
</tr>
<tr>
<td>−2.9</td>
<td>−1.8</td>
<td>Sestrin 1</td>
<td>Sestr1</td>
</tr>
<tr>
<td>−2.4</td>
<td>−1.1</td>
<td>Phosphodiesterase 4B, cAMP specific</td>
<td>Pde4b</td>
</tr>
<tr>
<td>−2.3</td>
<td>−1.9</td>
<td>Structural maintenance of chromosomes 4</td>
<td>Smc4</td>
</tr>
<tr>
<td>−2.2</td>
<td>−1.3</td>
<td>Sex comb on midleg-like 4 (Drosophila)</td>
<td>Scm4</td>
</tr>
<tr>
<td>−1.1</td>
<td>−2.2</td>
<td>RIKEN cDNA 490341B09 gene</td>
<td>490341B09Rik</td>
</tr>
<tr>
<td>−2.0</td>
<td>−1.9</td>
<td>Chemokine (C-X-C motif) receptor 4</td>
<td>Cxcr4</td>
</tr>
<tr>
<td>−2.0</td>
<td>−1.6</td>
<td>Kruppel-like factor 3 (basic)</td>
<td>Klf3</td>
</tr>
<tr>
<td>−2.0</td>
<td>−1.7</td>
<td>CD28</td>
<td>Cd28</td>
</tr>
<tr>
<td>−2.0</td>
<td>−1.6</td>
<td>Serum/glucocorticoid regulated kinase</td>
<td>Sgk</td>
</tr>
<tr>
<td>−2.0</td>
<td>−0.9</td>
<td>CXXC finger 5</td>
<td>Cxxc5</td>
</tr>
<tr>
<td>−2.0</td>
<td>−2.0</td>
<td>S100 calcium binding protein A10 (calpactin)</td>
<td>S100a10</td>
</tr>
</tbody>
</table>

* Fold change relative to 0 h (no treatment) is shown as a log2 value.
FIGURE 3. Acute infection activates the IRE-1/XBP-1 pathway in CD8⁺ T cells. A, Splicing status of XBP-1 mRNA in total CD8⁺ T cells purified from uninfected or LCMV-infected mice at day 8 p.i. Each lane represents an individual animal. B, The XBP-1-splicing reporter system. After removal of the 26-nt intron, the Venus-GFP cDNA becomes in-frame in the reporter construct. The reporter construct lacks the DNA binding domain (DBD) to prevent a dominant negative action of the truncated XBP-1 protein (28). TA, transcriptional activating domain. C, Venus-GFP levels in splenic dendritic cells of ERAI transgenic mice. Plots are gated on CD3⁻ CD19⁻ CD11c⁺ population. D, WT and ERAI transgenic (Tg) reporter mice were infected with LCMV, and splenocytes stained with Dgp33 tetramer on day 8. Plots are gated on CD8⁺ cells. The percentage of gp33-specific population within CD8⁺ T cells (top) is shown. Venus-GFP levels in gated gp33-specific CD8⁺ T cells (bottom) are shown. E, Mean fluorescence intensity (MFI) of Venus-GFP within KLRG1low or KLRG1high gp33-specific CD8⁺ T cell populations at day 8 p.i. Results indicate the mean ± SEM (n = 3–4 mice). F, OT-I cells expressing the XBP-1 splicing reporter or mock construct were obtained from mice reconstituted with retrovirally transduced bone marrow cells. These OT-I cells were transferred to host mice that were subsequently infected with 3000 CFU LM-OVA. Some infected animals were rested for 63 days, then given a high dose (1 × 10⁶ CFU) of LM-OVA, and analyzed 3 days later (d63+3). Plots are gated on OT-I cells with Thy1.1 transduction marker. The percentage of the gated OT-1 cells within each quadrant is shown. G, Splicing status of XBP-1 mRNA in naive CD44⁺ OT-I cells (N) or OT-I cells from mice that had received 10⁴ naive OT-I cells and were then infected with LM-OVA. H, Splicing status of XBP-1 mRNA in naive CD44⁺ P14 cells (N) or P14 cells from LCMV-infected mice that had received 10⁴ naive P14 cells. Some previously infected mice were challenged with 2 × 10⁶ CFU of LM-GP, and analyzed after 4 days (d36+4).
ERAI mice demonstrated XBP-1 splicing activity 8 days p.i. (Fig. 3D). When costained with KLRG1, the splicing activity was detectable in both KLRG1low and KLRG1high populations, but was significantly enriched in the KLRG1high terminal effector population (Fig. 3E).

Splicing of XBP-1u mRNA in effector CD8+ T cells was also triggered during a bacterial infection with LM-OVA (Fig. 3F and G). Similar to LCMV infection, the splicing activity was skewed to the KLRG1high population in effector CD8+ T cells specific for OVA (Fig. 3F). Time-course analyses showed that XBP-1 mRNA splicing mainly occurred during primary expansion (~day 7 or 8 p.i.) and secondary expansion after rechallenge of Ag-specific CD8+ T cells (Fig. 3, F–H). These results demonstrated that the IRE-1/XBP-1 splicing response is activated in effector CD8+ T cells during acute infection, and suggest a correlation between high levels of XBP-1s and terminal differentiation of effector CD8+ T cells.

**Overexpression of XBP-1s enhances KLRG1 levels on effector CD8+ T cells**

Enrichment of the XBP-1 splicing activity in KLRG1high effector cells suggested that overexpression of XBP-1s would promote terminal differentiation. OT-I/RAG1−/−/− CD8+ T cells were stimulated in vitro to allow retroviral transduction of various forms of XBP-1. The transduced OT-I/RAG1−/−/− CD8+ T cells were infected with LM-OVA, and KLRG1 expression was monitored.

**FIGURE 4.** Overexpression of XBP-1s enhances KLRG1 expression on effector CD8+ T cells. A, OT-I/RAG1−/−/− cells transduced with retrovirus encoding XBP-1u or XBP-1s were sorted based on the expression of Thy1.1 transduction marker, and 10^6 cells were transferred to host mice that were subsequently infected with 3000 CFU of LM-OVA. Populations of transduced OT-I/RAG1−/−/− cells (Thy1.1+) in the peripheral blood after infection are shown. Data are gated on CD8+ cells. The percentage of transduced OT-I/RAG1−/−/− cells within the CD8+ population is shown. B, Graphic representation of A with the mean ± SEM for n = 8–16 mice. C, KLRG1 levels on transduced OT-I/RAG1−/−/− cells following LM-OVA infection. D, LM-OVA-infected mice containing mock- or XBP-1s-transduced OT-I/RAG1−/−/− cells were treated with ampicillin, starting at 24 h p.i. KLRG1 levels of OT-I/RAG1−/−/− cells are shown. The percentage of KLRG1high population in OT-I/RAG1−/−/− cells with ampicillin treatment on day 7, p.i. with the mean ± SEM for n = 4–5 mice. E, KLRG1 levels of OT-I/RAG1−/−/− cells transduced with XBP-1u, XBP-1s, or T-bet and cultured in vitro for 10 days.
XBP-1. Transduced OT-I/RAG1<sup>−/−</sup> cells, marked by Thy1.1 expression, were sorted and adoptively transferred (10<sup>6</sup> cells/mouse) into Thy1.1-negative host mice that were subsequently infected with 3000 CFU LM-OVA. After infection, XBP-1<sup>−/−</sup>, XBP-1<sup>−/+</sup>, and mock-transduced OT-I/RAG1<sup>−/−</sup> cells expanded and contracted with similar kinetics (Fig. 4, A and B). Cytokine expression in these OT-I/RAG1<sup>−/−</sup> effector cells at day 7 p.i. following 4 h of peptide stimulation was not significantly affected (data not shown). However, KLRG1 levels on XBP-1<sup>−/−</sup> transduced effector OT-I/RAG1<sup>−/−</sup> cells were clearly higher at day 7 p.i. than on mock-transduced cells, and the higher expression levels were maintained thereafter (Fig. 4C). XBP-1<sup>−/−</sup> overexpression had no such enhancing effect. Following <i>Listeria</i> infection, shortening the infectious period by antibiotic treatment hampers the terminal differentiation of effector CD8<sup>+</sup> T cells (4, 30). Accordingly, ampicillin treatment starting at 24 h p.i. diminished the differentiation of mock-transduced OT-I/RAG1<sup>−/−</sup> cells into the KLRG1<sup>high</sup> population, and this effect was reversed by retroviral expression of XBP-1s (Fig. 4D). In contrast to retroviral expression of T-bet, which is known to regulate effector CD8<sup>+</sup> T cell differentiation (4, 37), KLRG1 expression was not induced by XBP-1s expression itself during 10 days of in vitro culture with IL-2 (Fig. 4E). These results suggest that XBP-1s potentiates KLRG1 levels on effector CD8<sup>+</sup> T cells but does not directly control the expression.

**Discussion**

In the present study, we demonstrated that the IRE-1/XBP-1 splicing machinery, known to be involved in the UPR, is activated in effector CD8<sup>+</sup> T cells during acute infection. IL-2 signals (as well as IL-4 and IL-15 in vitro) up-regulate XBP-1 mRNA in CD8<sup>+</sup> T cells.
cells in vivo, whereas TCR stimulation induces splicing and the generation of XBP-1s in vitro. Previous gene profiling studies showed that XBP-1 mRNA is up-regulated by IL-2 in vitro in human PBMC and mouse CD4+ T cells (39–42), suggesting a common mechanism of XBP-1 induction in T cells. Furthermore, we showed that XBP-1s contributes to driving terminal differentiation of effector CD8+ T cells. IRE-1 is an ER resident kinase/RNase that senses ER stress and is responsible for splicing XBP-1u mRNA (16, 17). When the UPR is pharmacologically induced in human cell lines, IRE-1 activities are quickly attenuated, compared with the other two pathways of UPR (22). Interestingly, under persistent ER stress, cells survive longer when the IRE-1 RNase activity is artificially sustained (22). Thus, the IRE-1/XBP-1 pathway affects cell fate decisions between cytotoxic and proapoptotic outcomes by the UPR. We consistently observed that the level of XBP-1s waned 8–24 h after anti-CD3 and anti-CD28 mAb stimulation (Fig. 2), suggesting that CD8+ T cells use a similar mechanism to turn this pathway off. Our gain-of-function and loss-of-function studies suggested a positive regulatory role for XBP-1s in KLRG1 expression. Unlike T-bet, however, overexpression of XBP-1s itself did not induce KLRG1 expression on CD8+ T cells in vitro (Fig. 4E). In addition, XBP-1s did not significantly affect KLRG1 levels on responding CD8+ T cells on day 5 following infection (Fig. 4C), when the cell fate commitment to terminal effectors vs memory precursor cells has already begun (4, 5). It has been reported that KLRG1 expression is associated with extensive cell division (43). Therefore, we assume that XBP-1s supports, rather than directs, differentiation of CD8+ T cells toward end-stage effector cells, possibly by affecting cell survival or proliferation.

The induction of XBP-1 mRNA and regulation of the unique splicing in CD8+ T cells appeared analogous to that in B cells. XBP-1u mRNA is induced in B cells by IL-4, but splicing to XBP-1s mRNA requires further stimulation with LPS and/or CD40 engagement (26). XBP-1 has a nonredundant role in the differentiation of B cells into plasma cells (25, 26), whereas one of the other arms of UPR, the PERK/eIF2α pathway, is not significantly involved in this process (44, 45). Our DNA microarray data showed that ATF4 mRNA, which is downstream of the PERK/eIF2α pathway, is also up-regulated in CD8+ T cells after IL-2 complex treatment (Table I). In future, it will be intriguing to examine the role of other pathways of the UPR in CD8+ T cell responses.

Virus infection activates the UPR in host cells due to the massive production of viral proteins (46), raising the question of whether this is happening in our in vivo studies. LCMV can infect T cells, but at a very low rate (<1%), as judged by intracellular staining for LCMV nucleoprotein (47). Furthermore, splicing of XBP-1u mRNA was also evident in CD8+ T cells after bacterial infection (Fig. 3, F and G). Therefore, it is not likely that the activation of XBP-1 splicing machinery in CD8+ T cells is a consequence of direct infection. In vitro experiments demonstrating the splicing of XBP-1 mRNA after TCR ligation (Fig. 2) further reinforce this conclusion.

Does the activation of the XBP-1 splicing machinery in CD8+ T cells represent induction of the UPR? Effector CD8+ T cells produce many cytokines and cytotoxic molecules, and calcium release from the ER is induced upon TCR ligation, both of which potentially cause ER stress. However, a Gene Expression Omnibus database search (GSE10239 (5), and GSE9650 (48)) and our preliminary real-time PCR analyses (data not shown) revealed that UPR target genes such as Bip (Hspa5), CHOP (Ddit3), ERdj4 (Dnajb9), and EDEM (Edem1) were not significantly increased in CD8+ T cells during the course of LCMV infection. Furthermore, in contrast to our expectation, cytokine production by CD8+ T cells during a brief period of Ag stimulation in vitro was not changed by the forced expression of XBP-1s or a null mutation of XBP-1 (data not shown). XBP-1 may be required for the sustained production of these effector cytokines, similar to its role in μ chain production in B cells (49). UPR induction in the course of plasma cell differentiation is well documented (14, 50). Despite the almost complete block of plasma cell differentiation in the absence of XBP-1 (25), however, Iwakoshi et al. (26) described that induction of ER chaperones including GRP78 (Bip) and GRP94 is only slightly impaired in XBP-1−/− B cells. Furthermore, Tirioh et al. (49) reported only a minor role for XBP-1 in ER quality control of primary B cells. ChIP-on-Chip analysis of XBP-1 using different cell types identified a number of cell type- and condition-specific target genes (20). These observations suggest an as yet unknown role for XBP-1 beyond that in the UPR, which may be applicable to CD8+ T cell responses. It is also possible that UPR target gene products are simply maintained at pre-existing levels by XBP-1s during the dramatic burst of proliferation of Ag-specific CD8+ T cells responding to pathogen infection (1).

In summary, we have demonstrated the activation of IRE-1/XBP-1 splicing machinery in CD8+ T cells in a physiological context. These findings also suggest that the stress control pathway in the ER contributes to the differentiation of effector CD8+ T cells in vivo.

Acknowledgments

We thank Beverly Dere, Xiao-cun Pan, and Biswajit Paul for excellent technical support. We also thank Hao Shen for LM-OVA and LM-GP33, Philippa Marrack for the pMit retrovirus vector, Masayuki Miura for ERAl transgenic mice and ERAl DNA constructs, and Laurie H. Glimcher for XBP-1/IRAG2−/− blastocyst chimeras and the retroviral vector containing T-bet cDNA.

Disclosures

The authors have no financial conflict of interest.

References
